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Abstract 66 
INTRODUCTION: The presymptomatic phase of neurodegenerative disease can last many years, with 67 
sustained cognitive function despite progressive atrophy. We investigate this phenomenon in familial 68 
Frontotemporal dementia (FTD). 69 
METHODS: We studied 121 presymptomatic FTD mutation carriers and 134 family members without 70 
mutations, using multivariate data-driven approach to link cognitive performance with both structural and 71 
functional magnetic resonance imaging. Atrophy and brain network connectivity were compared between 72 
groups, in relation to the time from expected symptom onset.  73 
 RESULTS: There were group differences in brain structure and function, in the absence of differences in 74 
cognitive performance. Specifically, we identified behaviourally-relevant structural and functional network 75 
differences. Structure-function relationships were similar in both groups, but coupling between functional 76 
connectivity and cognition was stronger for carriers than for non-carriers, and increased with proximity to 77 
the expected onset of disease.  78 
DISCUSSION: Our findings suggest that maintenance of functional network connectivity enables carriers to 79 
maintain cognitive performance.   80 
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 81 
1. Introduction 82 
Across the adult healthy lifespan, the structural and functional properties of brain networks are coupled, 83 
and both are predictive of cognitive ability [1,2]. The connections between structure, function and 84 
performance have been influential in developing current models of ageing and neurodegeneration [3–5]. 85 
However, this work contrasts with the emerging evidence of neuropathological and structural changes 86 
many years before the onset of symptoms of Alzheimer’s disease and frontotemporal dementia (FTD) [6–87 
8]. Genetic FTD with highly-penetrant gene mutations provides the opportunity to examine the precursors 88 
of symptomatic disease. Three main genes account for 10-20% of FTD cases: chromosome 9 open reading 89 
frame 72 (C9orf72), granulin (GRN) and microtubule-associated protein tau (MAPT). These genes vary in 90 
their phenotypic expression and in the age of onset [9]. Despite pleiotropy [10], environmental and 91 
secondary genetic moderation [11,12] all three mutations cause significant structural brain changes in key 92 
regions over a decade before the expected age of disease onset [7,13], confirmed by longitudinal studies 93 
[14,15]. 94 
The divergence between early structural change and late cognitive decline begs the question: how do 95 
presymptomatic mutation carriers stay so well in the face of progressive atrophy? We propose that the 96 
answer lies in the maintenance of network dynamics and functional organisation [16]. Across the lifespan, 97 
functional brain network connectivity predicts cognitive status [17], and this connectivity-cognition 98 
relationship becomes stronger with age [18–20]. 99 
Our overarching hypothesis is that for those at genetic risk of dementia, the maintenance of network 100 
connectivity prevents the manifestation of symptoms despite progressive structural changes. A challenge 101 
is that neither the anatomical and functional substrates of cognition nor the targets of neurodegenerative 102 
disease are mediated by single brain regions: they are distributed across multi-level and interactive 103 
networks. We therefore used a multivariate data-driven approach to identify differences in the 104 
multidimensional brain-behaviour relationship between presymptomatic carriers and non-carriers of 105 
mutations in FTD genes. We identified key brain networks [21] from a large independent population-based 106 
age-matched dataset [22]. 107 
We tested three key hypotheses: (i) presymptomatic carriers differ from non-carriers in brain structure and 108 
brain function, but not in cognitive function, (ii) brain structure and function correlate with performance in 109 
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both groups, but functional network indices are stronger predictors of cognition in carriers, and (iii) the 110 
dependence on network integrity for maintaining cognitive functioning increases as carriers approach the 111 
onset of symptoms. 112 
2. Methods 113 
2.1. Participants 114 
Thirteen research sites across Europe and Canada recruited participants as part of an international 115 
multicentre partnership, the Genetic Frontotemporal Initiative (GENFI). 313 participants had usable 116 
structural and resting state functional magnetic resonance imaging data (MRI) [7,13]. The study was 117 
approved by the institutional review boards for each site, and participants providing written informed 118 
consent. Inclusion criteria included anyone over the age of 18, who is symptomatic or a an asymptomatic 119 
first-degree relative. Five participants were excluded due to excessive head motion (see below), resulting 120 
in 308 datasets for further analysis. 121 
Participants were genotyped based on whether they carried a pathogenic mutation in MAPT, GRN 122 
and C9orf72. Mutation carriers were classified as either symptomatic or presymptomatic based on 123 
clinician evaluation. Participants were only classified as symptomatic if the clinician judged that symptoms 124 
were present, consistent with a diagnosis of a degenerative disorder, and progressive in nature. Additional 125 
group of controls, termed non-carriers, comprised of mutation-negative family members. In this study, 126 
we focus on non-carriers (NC, N=134) and presymptomatic carriers (PSC, N=121). Participants and site 127 
investigators were blinded to the research genotyping, although a minority of participants had undergone 128 
predictive testing outwith the GENFI study. See Table 1 for demographic information and Table 2 for 129 
behavioural, cognitive and neuropsychological information of both groups. In keeping with other GENFI 130 
reports, the years to expected onset (EYO) were calculated as the difference between age at assessment 131 
and mean age at onset within the family [7]. 132 
 133 
2.2. Neurocognitive assessment 134 
Each participant completed a standard clinical assessment consisting of medical history, family history, 135 
functional status and physical examination, in complement with collateral history from a family member or 136 
a close friend. In the current study 13 behavioural measures of cognitive function were correlated with 137 
neuroimaging measures. These included the Uniform Data Set [23]: the Logical Memory subtest of the 138 
Wechsler Memory Scale-Revised with Immediate and Delayed Recall scores, Digit Span forwards and 139 
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backwards from the Wechsler Memory Scale-Revised, a Digit Symbol Task, Parts A and B of the Trail Making 140 
Test, the short version of the Boston Naming Test, and Category Fluency (animals). Additional tests included 141 
Letter Fluency, Wechsler Abbreviated Scale of Intelligence Block Design task, and the Mini-Mental State 142 
Examination. Latency measures for the Trail Making Test were inverted so that higher values across all tests 143 
reflect better performance. 144 
 145 
2.3. Neuroimaging assessment 146 
Figure 1 provides a schematic representation of imaging data processing pipeline and the analysis strategy 147 
for linking brain-behaviour data. MRI data were acquired using 3T scanners and 1.5T where no 3T scanning 148 
was available from various vendors, with optimised scanning protocols to maximise synchronisation across 149 
scanners and sites [7,13]. A 3D-structural MRI was acquired on each participant using T1-weighted 150 
Magnetic Prepared Rapid Gradient Echo (MPRAGE) sequence over at least 283s (283-462s) and had a 151 
median isotropic resolution of 1.1mm (1-1.3mm), repetition time of 2000ms (6.6-2400), echo time of 2.9ms 152 
(2.6-3.5ms), inversion time of 8ms (8-9ms), and field of view 256x256x208mm (192-256x192-256x192-153 
208mm). The co-registered T1 images were segmented to extract probabilistic maps of 6 tissue classes: 154 
grey matter (GM), white matter (WM), cerebrospinal fluid (CSF), bone, soft tissue, and residual noise. The 155 
native-space GM and WM images were submitted to diffeomorphic registration to create equally 156 
represented gene-group template images [DARTEL; 24]. The templates for all tissue types were normalised 157 
to the Montreal Neurological Institute template using a 12-parameter affine transformation. The 158 
normalised images were smoothed using an 8-mm Gaussian kernel.  159 
For resting state fMRI measurements, Echo-Planar Imaging (EPI) data were acquired with at least six 160 
minutes of scanning. Analogous imaging sequences were developed by the GENFI Imaging Core team, and 161 
used at each GENFI study site to accommodate different scanner models and field strengths. EPI data were 162 
acquired over at least 300s (inter-quartile range 309-440) and had a median repetition time of 2200ms 163 
(2200-3000ms), echo time of 30ms, in-plane resolution of 2.75x2.75mm (2.75-3.31 x 2.75-3.31), and slice 164 
thickness of 3.3mm (3.0-3.3). 165 
The imaging data were analysed using Automatic Analysis [AA 4.0, 25] pipelines and modules which called 166 
relevant functions from SPM12 [26]. To quantify the total motion for each participant, the root mean 167 
square volume-to-volume displacement was computed using the approach of Jenkinson et al [27]. 168 
Participants with 3.5 or more standard deviations above the group mean motion displacement were 169 
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excluded from further analysis (N = 5). To further ensure that potential group bias in head motion did not 170 
affect later analysis of connectivity, we took three further steps: i) fMRI data was further postprocessed 171 
using whole-brain Independent Component Analysis (ICA) of single subject time-series denoising, with 172 
noise components selected and removed automatically using a priori heuristics using the ICA-based 173 
algorithm [28], ii) postprocessing of network node time-series (see below) and iii) a subject-specific 174 
estimate of head movement for each participant [27] included as a covariate in group-level analysis [29]. 175 
2.4. Network definition 176 
The location of the key cortical regions in each network was identified by spatial-ICA in an independent 177 
dataset of 298 age-matched healthy individuals from a large population-based cohort [22]. Full details 178 
about preprocessing and node definition are described previously [30]. Four networks commonly affected 179 
by neurodegenerative diseases including FTD [21] were identified by spatially matching to pre-existing 180 
templates [31]. The node time-series were defined as the first principal component resulting from the 181 
singular value decomposition of voxels in an 8-mm radius sphere, which was centred on the peak voxel for 182 
each node [18]. Visual representation of the spatial distribution of the nodes is shown in Figure 2.  183 
We aimed to further reduce the effects of noise confounds on functional connectivity effects of node time-184 
series using general linear model (GLM) [29]. This model included linear trends, expansions of realignment 185 
parameters, as well as average signal in WM and CSF, including their derivative and quadratic regressors 186 
from the time-courses of each node. The WM and CSF signals were created by using the average signal 187 
across all voxels with corresponding tissue probability larger than 0.7 in associated tissue probability maps 188 
available in SPM12. A band-pass filter (0.0078-0.1 Hz) was implemented by including a discrete cosine 189 
transform set in the GLM. Finally, the functional connectivity (FC) between each pair of nodes was 190 
computed using Pearson’s correlation on postprocessed time-series. 191 
 192 
2.5. Statistical analysis 193 
2.5.1. Group differences in brain structure, function and cognition 194 
To assess the group-differences in neuroimaging and behavioural dataset we used multiple linear 195 
regression with a well-conditioned shrinkage regularization [32,33] and 10-Fold Cross–Validation [34]. In 196 
the analysis of brain structure we used as independent variables the mean grey matter volume (GMV) of 197 
the 246 brain nodes in the Brainnetome atlas [35]. The Brainnetome atlas was developed to link functional 198 
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and structural characteristics of the human brain [35] and provides a fine-grained whole brain parcellation 199 
with a superior representation of age-related differences in brain structure compared to other cortical 200 
parcellation schemes [36,37]. In the analysis of brain function, we used the functional connectivity between 201 
15 nodes, which were part of the four large-scale functional networks described above. In the analysis of 202 
cognitive function, the independent variables comprised the performance measures on the 13 203 
neuropsychological tests performed outside of the scanner. In all three analyses the dependent variable 204 
was the genetic status (PSC vs NC) including age as a covariate of no interest. GENFI’s large-sampled cohort 205 
was created using harmonized multi-site neuroimaging data. Although, scanning protocols were optimised 206 
to maximise comparability across scanners and sites [7,13], different scanning platforms can introduce 207 
systematic differences which might confound true effects of interest [38]. Therefore, in the analysis of 208 
neuroimaging data we included scanner site and head motion as additional covariates of no interest.  209 
2.5.2. Brain-behaviour relationships 210 
For the brain-behaviour analysis, we adopted a two-level procedure. In the first-level analysis, we assessed 211 
the multidimensional brain-behaviour relationships using partial least squares [39]. This analysis described 212 
the linear relationships between the two multivariate datasets, namely neuroimaging (either GMV or FC) 213 
and behavioural performance, by providing pairs of latent variables (Brain-LVs and Cognition-LVs) as linear 214 
combinations of the original variables which are optimised to maximise their covariance. Namely, dataset 215 
1 consisted of a brain feature set, which could be either grey matter volume (GMV dataset) or functional 216 
connectivity strength between pairs of regions for each individual (FC dataset). Dataset 2 included the 217 
performance measures on the 13 tests (i.e. Cognition dataset), as considered in the multiple linear 218 
regression analysis of group differences in cognition. Covariates of no interest included head motion, 219 
scanner site, gender and handedness. In addition, we also included average GMV across all 15 nodes as a 220 
covariate of no interest in the FC-behaviour analysis to ensure that the observed effects are over and above 221 
differences in the level of atrophy. 222 
Next, we tested whether the identified behaviourally-relevant LVs of brain structure and function were 223 
differentially expressed by NC and PSC as a function of expected years to onset. To this end, we performed 224 
a second-level analysis using multiple linear regression with robust fitting algorithm as implemented in 225 
matlab’s function “fitlm.m”. Independent variables included subjects’ brain scores from first level PLS 226 
(either Structure-LV or Function-LV subject scores), group information, expected years to onset and their 227 
interaction terms (e.g. brain scores x group, brain scores x years to expected onset, etc.). The dependent 228 
variable was subjects’ cognitive scores from the first level analysis in the corresponding PLS (Cognition-LV). 229 
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Given that the interaction effects were derived from continuous variables, we tested and interpreted 230 
interactions based on simple slope analysis and slope difference tests [40–42]. Covariates of no interest 231 
included gender, handedness, head movement and education (Figure 1). In addition, we included average 232 
GMV across all 15 nodes as a covariate in the FC-behaviour analysis to ensure that the observed effects are 233 
over and above differences in the level of atrophy. 234 
3. Results 235 
3.1. Group differences in neuroimaging and cognitive data 236 
Brain structure 237 
The multiple linear regression model testing for overall group differences in grey matter volume between 238 
PSC and NC was significant (r=.14, p=.025), reflecting expected presymptomatic differences in brain-wide 239 
atrophy. The frontal, parietal and subcortical regions had most atrophy in PSC (Figure 3). As expected, the 240 
group difference in grey matter volume of these regions increased as EYO decreased, see Supplementary 241 
Materials. 242 
Brain Function 243 
The multiple linear regression model testing for overall group differences in functional connectivity 244 
between PSC and NC was marginally significant (r=.12, p=.049). The pattern of connectivity indicated mainly 245 
increased connectivity between SN-DMN and SN-FPN in presymptomatic carriers, coupled with decreased 246 
connectivity within the networks and DMN-FPN connectivity (Figure 3). 247 
Cognitive Function 248 
We did not identify group differences in cognition and behaviour (r=.002, p=.807), confirming the 249 
impression of “healthy” status among presymptomatic carriers. However, in the next section, we consider 250 
the relationships between structure, function and cognition that underlie this maintenance of cognitive 251 
function.  252 
3.2. Brain-behaviour relationships  253 
Structure-cognition 254 
Partial least squares analysis of grey matter volume and cognition identified one significant pair of latent 255 
variables (r = .40, p = .019). This volumetric latent variable expressed negative loadings in frontal (superior 256 
frontal gyrus, precentral gyrus, paracentral lobule), parietal (postcentral gyrus, precuneus, superior and 257 
inferior parietal lobule) and occipital (lateral and medial occipital cortex) regions and positive loadings in 258 
11 | P a g e  
 
parahippocampal and hippocampal regions in addition to inferior temporal and insular cortex (Figure 4). 259 
The Cognition-LV profile expressed positively a large array of cognitive tests, with strongest values on 260 
delayed memory, Trail Making, Digit Symbol, Boston Naming and Fluency tests. The positive correlation 261 
between volumetric and cognitive LV’s confirms the expected relationship across the cohort as a whole, 262 
between cortical grey matter volume and both executive, language and mnemonic function (Figure 4). 263 
To understand the structure-cognition relationship in each group and in relation to the expected 264 
years of onset, we performed a second-level interaction analysis using a regression model: we entered 265 
Cognition-LV subject scores as dependent variable, and grey matter volume LV subject scores, genetic 266 
status (i.e. mutation carrier or non-carrier), expected years to onset and their interactions as independent 267 
variables in addition to covariates of no interest. The results indicated that the relationship between grey 268 
matter volume and cognition could not be explained by genetic status, expected years to onset or their 269 
interactions with grey matter volume LV subject scores. There was no evidence for genetic status- and 270 
onset-dependent differences (over and above ageing and other covariates) in the associations between 271 
grey matter volume and cognition in this analysis (Figure 4). 272 
Connectivity-Cognition 273 
PLS analysis of functional connectivity and cognition also identified one significant pair of LVs (Function-LV 274 
and Cognition-LV, r=.32, p=.020), see Figure 5. This Function-LV reflected weak between-network 275 
connectivity, coupled with strong within-network connectivity. This pattern indicates the segregation or 276 
modularity of large-scale brain networks. The Cognition-LV expressed all tests, with positive loading values 277 
indicating that higher performance on a wide range of cognitive tests is associated with stronger functional 278 
network segregation. Cognitive deficits were associated with loss of segregation, with increased between-279 
network connectivity and decreased within-network connectivity.  280 
To further test whether the observed behaviourally-relevant pattern of connectivity is differentially 281 
expressed between genetic status groups and expected years of onset, we constructed a second-level 282 
regression model with robust error estimates by including Function-LV subject scores, genetic status, 283 
expected years of onset and their interaction terms as independent variables and Cognition-LV as 284 
dependent variable in addition to covariates of no interest (Figure 5). 285 
We found evidence for significant interaction between expected years of onset and Function-LV (r=.21, 286 
p<.001) and between group and Function-LV (r=.16, p=.002) explaining unique variance in Cognition-LV. 287 
We used simple slope analysis and slope difference tests [40–42] to test formally for differences in the 288 
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relationship between Function-LV and Cognition-LV for PSC and NC. The relationship between Function-LV 289 
and Cognition-LV was stronger for PSC relative to NC (r=.16, p=.002), indicating the increasing importance 290 
of functional connectivity between the large-scale networks for PSC participants to maintain performance 291 
(Figure 5). 292 
For ease of interpretation and illustration, we also computed the correlation between Cognition-LV and 293 
Function-LV for high and low levels of expected years to onset (EYO) within each group separately, where 294 
the levels were taken to be 1 standard deviation above and below the mean values of EYO following the 295 
simple slopes approach [40–42]. The two EYO subgroups were labelled “near” and “far”, with “near” for 296 
EYO values close to zero (i.e. participant’s age is “near” the age at which disease symptoms were 297 
demonstrated in the family), and “far” for EYO being a largely negative value (i.e. participant’s age is “far” 298 
from the age at which disease symptoms were demonstrated in the family). The analysis indicated that as 299 
the EYO decreases (i.e. participant’s age is reaching the years of onset of symptoms) the relationship 300 
between functional connectivity and performance becomes stronger. This effect was highly significant in 301 
presymptomatic carriers (r=.31, p<.001) and tended towards significance in non-carriers (r=.12, p=.038, 302 
one-sided). The differences in effects between presymptomatic carriers and non-carriers was qualified by 303 
a significant interaction term (t=2.27, p=0.024, i.e. the effect in presymptomatic mutation carriers was 304 
statistically stronger than the effect detected in non-carriers). These findings indicate that the relationship 305 
between FC and cognition is stronger in PSC relative to NC, and that this relationship increases as a function 306 
of EYO. 307 
 308 
4. Discussion 309 
In the present study, we confirmed previous findings of group differences in brain structure and function, 310 
in the absence of differences in cognitive performance between non-carriers and presymptomatic carriers 311 
of FTD-related genetic mutations. But, while the relationship between structure and cognition was similar 312 
in both groups, the coupling between function and cognition was stronger for presymptomatic carriers, 313 
and increased as they approached the expected onset of disease.  314 
These results suggest that people can maintain good cognitive abilities and successful day-to-day 315 
functioning despite significant neuronal loss and atrophy. This disjunction between structure and function 316 
is a feature of healthy ageing, but we have shown that it also characterises presymptomatic FTD, over and 317 
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above the age effects in their other family members, despite widespread progressive atrophy. The 318 
multivariate approach reveals two key findings: (i) presymptomatic carriers express stronger between-319 
network and weaker within-network functional connectivity than age-matched non-carriers, and (ii) as 320 
carriers approach their estimated age of symptom onset, and atrophy becomes evident, the maintenance 321 
of good cognition is increasingly associated with sustaining balance of within- and between-network 322 
integration. 323 
This balance of within- and between-network connectivity is characteristic of segregated and specialized 324 
network organization of brain systems. Such functional segregation varies with physiological ageing 325 
[17,18,43], with cognitive function [18] and in individuals at risk for Alzheimer’s disease [44]. Graph-326 
theoretic quantification of network organisation confirms the relevance of modularity and efficiency to 327 
function in FTD [16]. Conversely, the loss of neural systems’ modularity mirrors the loss of functional 328 
specialization with age [45] and dementia [44]. Here, we show the significance of the maintenance of this 329 
functional network organisation, with a progressively stronger correlation with cognitive performance as 330 
seemingly healthy adults approach the age of expected onset of FTD. 331 
The uncoupling of brain function from brain structure indicates that there may be independent and 332 
synergistic effects of multiple factors leading to cognitive preservation. This is consistent with a previous 333 
work in healthy ageing where brain activity and connectivity provide independent and synergistic 334 
predictions of performance across the lifespan [19]. Therefore, future studies need to consider the 335 
independent and synergistic effects of many possible biomarkers, based on MRI, computed tomography, 336 
positron-emission tomography, CSF, blood and brain histopathology. For example, functional network 337 
impairment may be related to tau expression and tau pathology, amyloid load, or neurotransmitter deficits 338 
in neurodegenerative diseases, independent of atrophy [30,46–48]. Importantly, studies need to recognise 339 
the rich multivariate nature of cognition and of neuroimaging in order to improve stratification procedures, 340 
e.g. based on integrative approaches that explain individual differences in cognitive impairment [30,49]. 341 
On a clinical level, this may facilitate future studies to establish whether presymptomatic carriers who 342 
maintain such connectivity profiles and thereby neuropsychological function  in the presence of atrophy 343 
may have a lower risk of progression and better prognosis – information which will be important for future 344 
triallists, patients and carers. 345 
We also recognise the difficulty to determine a unique contribution of each factor (e.g. brain structure and 346 
brain function), given the increasing interaction between factors in advanced stages of disease [50]. This is 347 
further complicated by these alterations becoming irreversible with progression of neurodegeneration 348 
14 | P a g e  
 
[51]. This suggests that the critical interplay between multiple factors (including brain structure and 349 
function) may be better studied in the asymptomatic and preclinical stages as well as across the healthy 350 
lifespan, which could still be modifiable and their influences are likely to be more separable. 351 
Our findings agree with the model of compensation in the presymptomatic and early phases of 352 
Huntington’s disease, where network coupling predicted better cognitive performance [52]. In a recent 353 
longitudinal study a non-linear concave-down pattern of both brain activity and behaviour was present,  354 
despite a linear decline in brain volume over time, [53]. Similar effects have been observed also in healthy 355 
ageing and amnestic mild cognitive impairment, where greater connectivity with the default-mode network 356 
and weaker connectivity between default-mode network and dorsal-attention network was associated with 357 
higher cognitive status in both groups [54]. Network integrity may also play a role in compensatory 358 
mechanisms in non-cognitive symptoms, such as motor impairment in Parkinson’s disease [55]. 359 
Accordingly, increased network efficiency and connectivity has been shown in prodromal phases, followed 360 
by decreased local connectivity in symptomatic phases, suggesting the emergence and dissipation of neural 361 
compensation [56]. 362 
The current study has several limitations. First, despite the large size of the overall GENFI cohort, we did 363 
not analyse each genetic group separately. The subdivision of each clinical group (PSC, NC) by three genes 364 
would have led to small and unbalanced subgroups, lowering statistical power and robustness. Moreover, 365 
genetic FTD is also characterised by multiple mutations within MAPT and GRN, and pleiotropy of clinical 366 
phenotypes from the same mutation [10]. Pleiotropy of clinical phenotype is avoided by the study of 367 
presymptomatic carriers, but we cannot rule out pleiotropy of intermediate phenotypes expressed as say 368 
neural network diversity. In FTD as in other dementias, clinical heterogeneity is modified by environmental 369 
factors such as education [which may be a surrogate of cognitive reserve, 12,57]. In addition, our analysis 370 
included the estimated age of onset in some models, but we recognise that the precision of the estimated 371 
years of onset (based on family history of onset) varies across mutations and families [7,58], being highest 372 
for MAPT and low for C9ORF72 expansion. Genetic modifiers such as TMEM106B [59], APOE [60], have also 373 
been identified. Further work, with larger cohorts is required to test for gene-specific effects, and the role 374 
of environmental and genetic moderators on the relationships between brain structure, functional 375 
networks and cognition. The harmonisation of sequences and data acquisition protocols in this multi-site 376 
neuroimaging study aimed to reduce the susceptibility to systematic differences across scanning platforms, 377 
but residual site variance cannot be ruled out [38,61]. The inclusion of study site as a covariate of no interest 378 
[61] and the nature of our multivariate approach to identify shared signals between brain and behavioural 379 
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data reduce residual effects of scanner variance [38,62]. Future studies may use alternative brain measures 380 
that reflect differences in cortical surface and thickness estimates [63,64], or which infer neural 381 
connectivity directly from neurophysiology or from the separation of neurovascular from neuronal 382 
contributors to BOLD fMRI variance [18,65], given the confounding effects of age, drug or disease on 383 
neurovascular signals [66,67].  384 
The current study is cross-sectional. Therefore, we cannot infer longitudinal progression within subjects as 385 
the unambiguous cause of the effects we observe in relation to expected years of onset. Accumulating 386 
evidence suggests that network integrity serves to maintain performance with either physiological ageing 387 
or pathological conditions. However, longitudinal mediation studies and pharmacological or electroceutical 388 
interventions would be needed to prove its causal role in cognitive preservation. Finally, our findings are 389 
limited to autosomal dominant FTD, which represents a minority of FTD: generalisation to sporadic forms 390 
of disease would be speculative.  391 
In conclusion, we used a multivariate data-driven approach to demonstrate that brain functional integrity 392 
may facilitate presymptomatic carriers to maintain cognitive performance in the presence of progressive 393 
brain atrophy for years before the onset of symptoms. The multivariate approach to cognition and brain 394 
function is well-suited to address the effects of multiple interacting risk factors on biomarkers of the 395 
progression of neurodegeneration, ahead of clinical conversion to dementia. The approach and our findings 396 
have implications for the design of presymptomatic disease-modifying therapy trials, which are likely to 397 
rely initially on surrogate markers of brain health rather than clinical endpoints. 398 
  399 
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 625 
7. Tables 626 
Table 1. Demographics of participants included in the analysis, grouped by genetic status 627 
as non-carriers (NC) and presymptomatic carriers (PSC). * denotes whether demographics vary 628 
between NC and PSC groups. 629 
 630 
  631 
NC PSC X2 or F-test P -value
N 134 121
Mutated gene, n (%) 0.86 0.649
MAPT 17 (12.7) 19 (15.7)
GRN 77 (57.5) 63 (52.1)
C9Orf72 40 (29.9) 39 (32.2)
0.01 0.908
Male 53 (39.6) 47 (38.8)
Handedness, n (%) 0.06 0.806
Right-handed 122 (91) 107 (88.4)
2.68 0.103
Mean / SD 49 / 14 46 / 11
Range [Min/Max] 19 / 86 20 / 70
0.23 0.631
Mean / SD -10 / 12 -11 / 11
Range [Min/Max] -25 / 10 -25 / 10
0.05 0.826
Mean / SD 14 / 3 14 / 3
Range [Min/Max] 5 / 24 5 / 22
* Statistical test to indicate whether demographics vary between NC and PSC groups
Education (Years)
Gene Status Group Statistical tests*
Age (Years)
Gender, n (%)
Expected Years to Onset
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Table 2. Behavioural, cognitive and neuropsychological estimates in presymptomatic carriers and non-carriers 632 
 633 
NC PSC X2 P -value
Behavioural
Cambridge Behavioural Inventory—Revised (/180) 3.5 ( 5.4) 4.7 ( 10) 0.03 0.864
Mini-Mental State Examination 29.3 ( 1.1) 29.2 ( 1.3) < 0.01 0.963
Neuropsychological
Logical Memory—Immediate Recall 15.2 ( 5.6) 15.7 ( 5.6) 0.47 0.495
Logical Memory—Delayed Recall 14.1 ( 4.7) 14 ( 5) 0.97 0.356
Digit Span - Forwards 6.4 ( 1.2) 6.3 ( 1.3) 0.52 0.470
Digit Span - Backwards 4.9 ( 1.2) 4.8 ( 1.2) 1.62 0.203
Digit Symbol Task 32 ( 14.1) 35 ( 14) 0.35 0.556
Trail Making Test Part A 28.9 ( 17.2) 28.9 ( 11.5) 0.97 0.325
Trail Making Test Part B 72.5 ( 43.7) 72.3 ( 45.5) 0.02 0.895
Verbal Fluency - Letter 42 ( 12.2) 40.7 ( 15.1) 0.95 0.330
Verbal Fluency - Animal 23.3 ( 6) 23.7 ( 5.8) 0.58 0.445
Boston Naming Test 28.1 ( 2.1) 27.6 ( 2.7) 0.58 0.446
Block Design 41.8 ( 16.1) 42.5 ( 17.1) 0.17 0.683
* Statistical test to indicate whether scores vary between NC and PSC groups
Gene Status Group Statistical tests*
Cognitive
27 | P a g e  
 
8. Figures 634 
  635 
 636 
Figure 1. Schematic representation of data processing and analysis pipeline to test for 637 
brain-behaviour differences between presymptomatic carriers (PSC) and non-carriers (NC) as a 638 
function of expected years to onset (EYO) of symptoms, while controlling for covariates of no 639 
interest (Covs). Brain structural measures were based on the mean grey matter volume (GMV) in 640 
246 nodes, as defined in the Brainnetome atlas [35]. Brain functional measures were based on the 641 
functional connectivity between 15 nodes as part of four large-scale networks, which were defined 642 
in an independent cohort of 298 age-matched individuals part of the Cam-CAN dataset. 643 
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Figure 2. Visualisation of spatial localisation of the nodes part of the four large-scale 647 
networks and their mean functional connectivity (circular plot) across all participants in this study. 648 
Nodes and networks were defined in an independent cohort of 298 age-matched individuals part 649 
of the Cam-CAN dataset [30].The default mode network (DMN) contained five nodes: the ventral 650 
anterior cingulate cortex (vACC), dorsal and ventral posterior cingulate cortex (vPCC and dPCC), 651 
and right and left inferior parietal lobes (rIPL and lIPL). The salience network (SN) was defined 652 
using right and left anterior insular (rAI and lAI) and dorsal anterior cingulate cortex (dACC). The 653 
frontoparietal network (FPN) was defined using right and left anterior superior frontal gyrus 654 
(raSFG and laSFG), and right and left angular gyrus (rAG and lAG). The dorsal attention Network 655 
(DAN) was defined using right and left intraparietal sulcus (rIPS and lIPS). 656 
  657 
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 658 
Figure 3. Group differences between PSC and NC in grey matter volume (left panel) and 659 
functional connectivity between nodes within four large scale networks (right panel). Hot colour 660 
scheme indicates the strength of effect size of PSC showing higher GMV and FC than NC, while cold 661 
colour scheme indicates the opposite effect (i.e. NC > PSC). 662 
  663 
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 664 
Figure 4. PLS analysis of grey matter volume (GMV) and cognition indicating the spatial 665 
distribution of GMV loading values (a), where hot and cold colour schemes are used for the strength 666 
of positive and negative correlations with the profile of Cognitive LV (b). (c) The scatter plot on the 667 
left represents the relationship between subjects scores of GMV LV and Cognition LV for 668 
presymptomatic carriers (PSC) and non-carriers (NC). The scatter plots in the middle and right 669 
hand-side represent GMV-Cognition LV relationship as a function of expected years to onset (EYO, 670 
split in two groups, Near and Far, see text) in each genetic status group separately. 671 
  672 




Figure 5. PLS analysis of functional connectivity and cognition indicating the connectivity 675 
pattern of loading values (a), where hot and cold colour schemes are used for the strength of 676 
positive and negative correlations with the profile of Cognitive LV (b). (c) The scatter plot on the 677 
left represents the relationship between subjects scores of Function LV and Cognition LV for 678 
presymptomatic carriers (PSC) and non-carriers (NC). The scatter plots in the middle and right 679 
hand-side represents Function-Cognition LV relationship as a function of expected years to onset 680 
(EYO split in two groups, Near and Far, see text) in each genetic status group separately. This is 681 
also represented using a bar chart in (d), where continuous and dashed lines indicate significance 682 
of effect differences and difference in differences, respectively. † and * denote significant tests at 683 
p-value < 0.05 (one- and two-sided, respectively). 684 
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